A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Trial Profile

A Phase I Open-Label Dose Escalation Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Discontinued
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2007

At a glance

  • Drugs Siplizumab (Primary)
  • Indications Cutaneous T cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Jun 2007 Status changed from recruiting to discontinued.
    • 01 Feb 2007 The expected number of patients changed from 68 to 80 in February 2007.
    • 13 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top